Gene Therapy1
Gene Therapy1
Presented by:
Nurul Miza Shasheiha binti Abdul Mutalib -5089Wan Fathiah Nasuha binti Wan Nudri -5117Nurul Husna binti Muryadi -5088-
Researchers are studying gene therapy for a number of diseases, such as Severe combined immuno-deficiencies (SCID)
Hemophilia
Parkinson's disease Cancer HIV
1970: Friedmann and Roblin author of a paper in Science titled "Gene therapy for human genetic disease? cite the first attempt to perform gene therapy
1990:
The first approved gene therapy case at the National Institute of Health, U.K. It was performed on a four year old girl named Ashanti DaSilva. It was a treatment for a genetic defect that left her with an immune system deficiency New gene therapy approach repairs errors in messenger RNA derived from defective genes. This technique has the potential to treat the blood disorder Thalassaemia, Cystic fibrosis, and some cancers
Sickle cell disease is successfully treated in mice
1992: Doctor Claudio Bordignon working at the Vita-Salute San Raffaele University, Milan, Italy performed the first procedure of gene therapy using hematopoietic stem cells as vectors to deliver genes intended to correct hereditary diseases 1999: Death of Jesse Gelsinger in a gene-therapy experiment resulted in a significant setback to gene therapy research in the United States
2006: Scientists at the National Institutes of Health (Bethesda, Maryland) have successfully treated metastatic melanoma in two patients. This study constitutes one of the first demonstrations that gene therapy can be effective in treating cancer. 2007- 2011: Research is still ongoing and the number of diseases that has been treated successfully by gene therapy increases.
Retinal disease Colour blindness Adrenoleukodystrophy 2011: Medical community accepted that it can cure HIV as in 2008, Gero Hutter has cured a man from HIV using gene therapy
Result in permanent changes. Potential for offering a permanent therapeutic effect for all who inherit the target gene. Possibility of eliminating some diseases from a particular family. Also raises controversy: Some people view this type of therapy as unnatural, and liken it to "playing God. Others have concerns about the technical aspects.
Affects only the targeted cells in the patient, and is not passed to future generations. Short-lived because the cells of most tissues ultimately die and are replaced by new cells. Transporting the gene to the target cells or tissue is also problematic. Appropriate and acceptable for many disorders, including cystic fibrosis, muscular dystrophy, cancer, and certain infectious diseases.
GT utilizes the delivery of DNA into cells, which can be accomplished by a number of methods.
The two major classes of methods : recombinant viruses VIRAL VECTOR naked DNA or DNA complexes NONVIRAL VECTOR
Viruses have evolved a way of encapsulating and delivering their genes to human cells in a pathogenic manner. Scientists have tried to harness this ability by manipulating the viral genome to remove diseasecausing genes and insert therapeutic ones .
VIRAL VECTOR
Virus bind to their hosts and introduce their genetic material into the host cell. Plausible strategy for gene therapy, by removing the viral DNA and using the virus as a vehicle to deliver the therapeutic DNA.
The viruses used are altered to make them safe, although some risks still exist with gene therapy.
VIRUS
Many GT clinical trials rely on retroviruses or adenoviruses to deliver the desired gene.
Other viruses used as vectors include adeno-associated viruses, lentiviruses, pox viruses, alphaviruses, and herpes viruses. Differ in how well they transfer genes to the cells they recognize and are able to infect, and whether they alter the cells DNA permanently or temporarily
TYPES OF VIRUS
Are a tool commonly used by molecular biologists to deliver genetic material into cells.
Can be performed in vivo or in vitro. Viruses have evolved specialized molecular mechanisms to efficiently transport their genomes inside the cells they infect. Delivery of genes by a virus is termed transduction and the infected cells are described as transduced.
VIRAL VECTOR
Methods of non-viral gene delivery have also been explored using physical (carrier-free gene delivery) and chemical approaches (synthetic vector-based gene delivery).
Physical approaches, including Needle injection Electroporation Gene gun Ultrasound Hydrodynamic delivery employ a physical force that permeates the cell membrane and facilitates intracellular gene transfer
PHYSICAL METHOD
The simplest method of non-viral transfection. Clinical trials carried out of intramuscular injection of a naked DNA plasmid have occurred with some success; however, the expression has been very low in comparison to other methods of transfection.
I. NAKED DNA
This success, however, does not compare to that of the other methods, leading to research into more efficient methods for delivery of the naked DNA such as electroporation and the use of a "gene gun", which shoots DNA coated gold particles into the cell using high pressure gas.
CHEMICAL METHODS THAT ENHANCE THE DELIVERY OF GENE THERAPY -lipoplexes & polyplexes-
DNA must be protected from damage & its entry into the cell must be facilitated Plasmid DNA can be covered with lipids in an organized structure like a micelle or a liposome complexed with DNA it is called a lipoplex 3 types of lipids: anionic (negatively charged) neutral cationic (positively charged)
LIPOPLEXES
Initially, anionic and neutral lipids : -were used for the construction of lipoplexes for synthetic vectors. -but,there is little toxicity associated with them, -they are compatible with body fluids -there was a possibility of adapting them to be tissue specific -they are complicated turned to the cationic versions. Cationic lipids, due to their positive charge, -naturally complex with the negatively charged DNA. -their charge they interact with the cell membrane -endocytosis of the lipoplex occurs -DNA is released into the cytoplasm. -The cationic lipids also protect against degradation of the DNA by the cell.
Complexes of polymers with DNA are called polyplexes consist of cationic polymers and their production is regulated by ionic interactions. large difference compared to lipoplexes is that polyplexes cannot release their DNA load into the cytoplasm, End= co-transfection with endosome-lytic agents such as inactivated adenovirus must occur (to lyse the endosome that is made during endocytosis, the process by which the polyplex enters the cell)
POLYPLEXES
BLINDNESS
PARKINSONS DISEASE
blindness of inherited condition Lebers conginetal amaurosis - inherited disease caused by an abnormality in a gene called RPE65. - The condition appears at birth or in the first few months of life and causes progressive worse and loss of vision.
HOW IT WORKS??
used
harmless viruses enable access to the cells beneath the retinas of patients By using a very fine needle -safe in an extremely fragile tissue and can improve vision in a condition previously considered wholly untreatable.
http://www.youtube.com/watch?v=d_YJZn-ft_Q
BLINDNESS
PARKINSONS DISEASE
significantly improved the weakness of the symptoms such as tremors, motor skill problems, and rigidity Main- overactive brain region: the subthalamic nucleus should be introduced with gene that would produce GABAan inhibitory chemicalthen they could potentially quiet that brain region and alleviate tremors.
HOW IT WORKS??
Done
with local anesthesia, used a harmless, inactive virus [AAV-2 GAD] Deliver the GAD gene into patients subthalamic nucleus The gene instructs cells to begin making GABA neurotransmitters to re-establish the normal chemical balance that becomes dysfunctional as the disease progresses
For certain disease that do not have any cure except gene therapy, it could save many lives